Vandria
- Company typePrivate
- Founded2021
- HeadquartersLausanne, Switzerland
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Vandria firmographics
Firmographics- Name
- Vandria
- Legal name
- Vandria SA
- Website
- https://vandria.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Vandria industry classification
Industry- Product category
- Mitochondrial Therapeutics / Biopharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medicinal and Botanical Manufacturing (325411)
- SIC
- Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
Keywords
Where Vandria is headquartered
LocationHeadquarters
- HQ city
- Lausanne
- HQ country
- Switzerland
- HQ region
- Europe
Offices1 record
Markets served
Vandria business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Pharmaceutical Development and Licensing: Vandria develops novel drug candidates through clinical development and plans to either commercialize directly or partner with larger pharmaceutical companies for commercialization. Revenue would come from licensing deals, milestone payments, and royalties on approved drugs.
- Non-Dilutive Grant Funding: The company has secured over $4M in non-dilutive grant funding from InnoSuisse and Eurostars to support drug development programs.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels4 records
Vandria product offering
Product offeringCore offering
Vandria develops first-in-class small molecule mitophagy inducers that target a novel metabolic target in the cytosol to restore mitochondrial function, induce mitophagy, reduce toxic protein aggregation, and lower chronic inflammation. Its lead asset VNA-318 is an orally bioavailable, brain-penetrant small molecule for Alzheimer's disease and other CNS disorders that has completed Phase 1 clinical trials. The pipeline also includes VNA-052 for muscle diseases, additional NCEs for lung and liver indications, and a separate ferroptosis program, underpinned by 15+ years of discovery science and composition-of-matter patents.
Product overview
Vandria is a clinical stage biotech company developing first-in-class small molecule therapeutics targeting mitochondria for age-related diseases. The company's core offering consists of its lead CNS asset VNA-318, a brain-penetrant mitophagy inducer that has completed Phase 1 trials for Alzheimer's disease, alongside a pipeline of additional mitophagy-inducing small molecules (including VNA-052 for muscle diseases) addressing chronic diseases of the muscle, lung, and liver. The platform is underpinned by 15+ years of discovery science identifying a novel metabolic target. Vandria also operates a separate program targeting ferroptosis for neurodegenerative conditions.
Differentiator
Problem solved
Functional benefit
Products and services
- VNA-318 Orally bioavailable, first-in-class brain-penetrant small molecule mitophagy inducer with a dual mode of action for treating Alzheimer's disease and other CNS disorders. Provides immediate improvement in memory, learning, and cognitive function, paired with long-term disease-modifying effects including reduced neuroinflammation, reduced toxic protein aggregation, and improved mitochondrial function. Completed Phase 1 clinical trials in 2025.
- VNA-052 Mitophagy drug candidate in preclinical development for muscle diseases, supported by Eurostars grant funding. Being developed for inflammatory myopathies in collaboration with academic and industry partners.
- Mitophagy Platform (NCEs targeting Target A) Novel metabolic target platform enabling development of first-in-class small molecule New Chemical Entities (NCEs) that induce mitophagy to restore mitochondrial function and reduce chronic inflammation for treating age-related and chronic diseases of the CNS, muscle, lung, and liver.
- Ferroptosis Program Separate drug discovery program targeting ferroptosis, a form of cell death implicated in neurodegenerative diseases and ischemia reperfusion injury.
Quantifiable outcome
- Phase 1 trial showed statistically significant (p<0.001) and dose-dependent change in target engagement biomarker with single dosing
- +4 more outcomes
Companies that use Vandria
Customer profileSegments3 records
Ideal customer profiles3 records
Vandria technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Vandria partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered minor.
- Prof. Olivier Benveniste (Hôpital Pitié-Salpêtrière AP-HP, France)minorCollaboration partner for Eurostars grant supporting VNA-052 pre-clinical data in muscle program. Head of Department of Internal Medicine and Clinical Immunology.
- Biomeostasis (France)minorCollaboration partner for Eurostars grant supporting VNA-052 pre-clinical data in muscle program.
- Bi/ond Solutions (Netherlands)minorCollaboration partner for Eurostars grant supporting VNA-052 pre-clinical data in muscle program.
Scale indicators8 records
Recent moves4 records
Expansion highlights5 records
Vandria competitors and assessment
Company assessmentDirect peers
- Sage Therapeutics: Biopharmaceutical company developing CNS small molecule therapeutics, including for Alzheimer's and major depressive disorder. Comparable to Vandria in CNS small molecule focus and target indications including major depressive disorder and neurodegeneration.
- Annexon, Inc. Clinical-stage biopharmaceutical company developing novel therapies for neurodegeneration. Directly comparable to Vandria as a CNS-focused biotech pursuing a distinct mechanism of action in classical complement pathway-related neurological diseases with multiple Phase-stage programs.
- Aeovian Pharmaceuticals: Emerging biotech developing selective mTOR inhibitors for age-related diseases. Comparable to Vandria as a small, focused platform company pursuing novel mechanism therapies for aging indications, with similar Series-stage financing profile.
- BioAge Labs: Clinical-stage biotech developing medicines that target the biology of aging, with a platform approach to age-related disease therapeutics. Directly comparable to Vandria's strategy of leveraging a single novel target (mitochondrial biology) into multiple age-related indications, including muscle and metabolic diseases.
- Cassava Sciences: Clinical-stage biopharmaceutical company developing novel therapies for Alzheimer's disease. Directly comparable to Vandria as a small-molecule CNS developer specifically targeting Alzheimer's with a mechanism distinct from anti-amyloid antibodies.
- BioXcel Therapeutics: Clinical-stage biopharmaceutical company leveraging AI for drug development in neuroscience and immuno-oncology. Comparable to Vandria as a small CNS-focused biotech pursuing multiple neuroscience indications, with a similar focus on neuroinflammation mechanisms.
- AC Immune SA: Swiss-based clinical-stage biopharmaceutical company developing precision medicine for neurodegenerative diseases. Directly comparable to Vandria as a Lausanne-based CNS biotech with multiple programs across Alzheimer's and related neurodegeneration, also pursuing both small molecule and biologic approaches.
- Denali Therapeutics: Clinical-stage biotechnology company developing brain-penetrant small molecule therapeutics for neurodegenerative diseases. Directly comparable to Vandria in CNS focus, small molecule modality, and target engagement biomarker approach, with a similar platform-extensibility narrative across multiple neurological indications.
Broad incumbents
- Biogen Inc. Global biotechnology company and established leader in Alzheimer's disease with approved therapies (aducanumab, lecanemab partnership with Eisai). Comparable as a major incumbent in Vandria's primary indication with deep CNS development and commercialization capabilities, representing both a potential competitor and acquisition/partnering target.
- Eli Lilly and Company: Global pharmaceutical company with a leading Alzheimer's franchise (donanemab/kisunla) and broad CNS pipeline. Comparable as the dominant incumbent in the Alzheimer's market and a likely potential strategic acquirer or partner for Vandria's CNS program.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
Vandria social profiles
Digital presenceVandria financial estimates
Financial estimateRevenue estimate
Valuation estimate
Vandria leadership team
Management profileNumber of profiles
Profiles6 records
Vandria funding detail
Funding detailFunding overview
Funding rounds3 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Vandria M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Vandria
What does Vandria do?
Vandria develops first-in-class small molecule mitophagy inducers that target a novel metabolic target in the cytosol to restore mitochondrial function, induce mitophagy, reduce toxic protein aggregation, and lower chronic inflammation. Its lead asset VNA-318 is an orally bioavailable, brain-penetrant small molecule for Alzheimer's disease and other CNS disorders that has completed Phase 1 clinical trials. The pipeline also includes VNA-052 for muscle diseases, additional NCEs for lung and liver indications, and a separate ferroptosis program, underpinned by 15+ years of discovery science and composition-of-matter patents.
Is Vandria a public or private company?
Vandria is a private company. It is classified as venture growth investor backed and is currently operating.
When was Vandria founded?
Vandria was founded in 2021. It employs 1 to 10 people.
Where is Vandria based?
Vandria is headquartered in Lausanne, Switzerland, in the Europe region.
How does Vandria make money?
Two revenue lines are on record. Pharmaceutical Development and Licensing is the primary driver. The others are non-Dilutive Grant Funding.
Who are Vandria's main competitors?
Direct peers on record are Sage Therapeutics, Annexon, Inc., Aeovian Pharmaceuticals, BioAge Labs, Cassava Sciences, BioXcel Therapeutics, AC Immune SA and Denali Therapeutics. Broad incumbents are Biogen Inc. and Eli Lilly and Company.
Does Vandria have an API?
No public API is recorded for Vandria.
What industry is Vandria in?
Vandria's product category is Mitochondrial Therapeutics / Biopharmaceuticals. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2833.